Pharmacologic management of renal involvement in monogenic autoinflammatory diseases.

Ahmed Fayed, Mohamed Tharwat Hegazy, Jurgen Sota, Carla Gaggiano, Gaafar Ragab

Abstract readReview

In one paragraph

Review in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ahmed FayedNephrology Unit, Internal Medicine Department, Cairo University, Cairo, Egypt.

Mohamed Tharwat HegazyRheumatology and Clinical Immunology Unit, Internal Medicine Department, Cairo University, Cairo, Egypt.

Jurgen SotaDepartment of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy.

Carla GaggianoDepartment of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy.

Gaafar RagabRheumatology and Clinical Immunology Unit, Internal Medicine Department, Cairo University, Cairo, Egypt. gragab@kasralainy.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney involvement represents one of the main targets of the systemic inflammatory process and is underscored by a heterogeneous pathology ranging from amyloidosis to non-amyloid-related damage rooted in inflammasome activation. A thorough approach to monogenic autoinflammatory disorders (AIDs) includes identifying phenotypic patterns, comprehending pathophysiology, and customizing therapy to improve patients' quality of life. In this review, we will discuss some pharmacological aspects focusing on the kidney as a target in AIDs. A special emphasis will be placed on medications used for AIDs cases with renal impairment, as well as drug-induced nephrotoxicity in monogenic AIDs. Understanding the mechanisms of drug-induced nephrotoxicity and applying preventive measures are critical for safely managing monogenic AIDs with renal involvement.

Indexed as

AmyloidosisAutoinflammatory disordersDrugsInflammasomeKidneyMonogenicNephrotoxicity

Identifiers

PMID41680868

DOI10.1186/s40001-026-03936-6

PMCPMC12930578

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.